Trial Profile
Golimumab in Work productivity and Activity Impairment in Patient with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Feb 2020
Price :
$35
*
At a glance
- Drugs Golimumab (Primary)
- Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms GO-ART
- 15 Jun 2019 Final results from a non-interventional study in Germany assessing efficacy of Golimumab in patients with patients with rheumatoid arthritis, Ankylosing Spondylitis and psoriatic arthritis presented at the 20th Annual Congress of the European League Against Rheumatism
- 24 Oct 2018 Primary endpoint (Work Productivity Activity Impairment) has been met as pe result presented at 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
- 24 Oct 2018 Results assessing efficacy of Golimumab in patients with Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.